Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study.

IF 3.9
Matthias Augustin, Rudolf E Schopf, Sven R Quist, Nalan Kalyon, Ralph M von Kiedrowski
{"title":"Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study.","authors":"Matthias Augustin, Rudolf E Schopf, Sven R Quist, Nalan Kalyon, Ralph M von Kiedrowski","doi":"10.1080/09546634.2025.2500511","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.</p><p><strong>Methods: </strong>LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-interventional study on brodalumab in adult patients with plaque-type psoriasis assessed its short- and long-term impact on PROs in mild, moderate and severe psoriasis defined by Psoriasis Area Severity Index (PASI).</p><p><strong>Results: </strong>200 (31.3%) patients with severe (PASI ≥ 20), 263 (41.2%) with moderate (PASI = 10-19) and 168 (26.3%) with mild (PASI < 10) psoriasis were analyzed. In all severity groups a rapid and sustained reduction of mean(m) PASI was observed as of W2. 76.7, 84.9 and 82.0% of patients assessed their psoriasis as being clear/almost clear in mild, moderate and severe subgroups and mean Dermatological Life Quality Index improved from 11.2, 14.3 and 17.1 to 3.2, 2.9 and 3.8. 73.7% of patients rated brodalumab as being quite/very beneficial (Patient Benefit Index, PBI) and were quite/very satisfied with the treatment (TSQM-9). Regaining disease control and reducing physical impairment achieved highest PBI-scores.</p><p><strong>Conclusion: </strong>LIBERO confirms the benefit of brodalumab on PROs including rapid and complete clearance of skin lesions, quality of life and individual patient benefits - irrespective of their disease severity.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2500511"},"PeriodicalIF":3.9000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2025.2500511","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.

Methods: LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-interventional study on brodalumab in adult patients with plaque-type psoriasis assessed its short- and long-term impact on PROs in mild, moderate and severe psoriasis defined by Psoriasis Area Severity Index (PASI).

Results: 200 (31.3%) patients with severe (PASI ≥ 20), 263 (41.2%) with moderate (PASI = 10-19) and 168 (26.3%) with mild (PASI < 10) psoriasis were analyzed. In all severity groups a rapid and sustained reduction of mean(m) PASI was observed as of W2. 76.7, 84.9 and 82.0% of patients assessed their psoriasis as being clear/almost clear in mild, moderate and severe subgroups and mean Dermatological Life Quality Index improved from 11.2, 14.3 and 17.1 to 3.2, 2.9 and 3.8. 73.7% of patients rated brodalumab as being quite/very beneficial (Patient Benefit Index, PBI) and were quite/very satisfied with the treatment (TSQM-9). Regaining disease control and reducing physical impairment achieved highest PBI-scores.

Conclusion: LIBERO confirms the benefit of brodalumab on PROs including rapid and complete clearance of skin lesions, quality of life and individual patient benefits - irrespective of their disease severity.

牛皮癣的严重程度及其对患者报告结果(PROs)的影响:来自LIBERO研究的布罗达鲁单抗210 mg的真实世界证据
目的:在真实世界证据(RWE)条件下,IL-17受体A拮抗剂brodalumab 210 mg对不同银屑病严重程度组患者报告的结果(PROs)的益处只有有限的数据。方法:LIBERO是一项前瞻性、多中心、为期12周和52周(W)的非介入研究,该研究评估了布罗达鲁单抗对斑块型银屑病成年患者pro的短期和长期影响,该研究以银屑病区域严重程度指数(PASI)定义轻度、中度和重度银屑病。结果:重度(PASI≥20)患者200例(31.3%),中度(PASI = 10-19)患者263例(41.2%),轻度(PASI < 10)患者168例(26.3%)。在所有严重程度组中,观察到W2时平均PASI (m)的快速和持续下降。在轻度、中度和重度亚组中,76.7%、84.9%和82.0%的患者认为自己的牛皮癣清晰/几乎清晰,平均皮肤生活质量指数从11.2、14.3和17.1提高到3.2、2.9和3.8。73.7%的患者认为brodalumab相当/非常有益(Patient Benefit Index, PBI),对治疗相当/非常满意(TSQM-9)。恢复疾病控制和减少身体损伤获得了最高的pbi得分。结论:LIBERO证实了brodalumab对PROs的益处,包括快速和完全清除皮肤病变,生活质量和个体患者益处-无论其疾病严重程度如何。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信